Globe & Mail (Toronto, Canada) 1998 Leonard Zehr - Abstracts
| Globe & Mail (Toronto, Canada) 1998 Leonard Zehr | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| Algene implements sweeping reorganization. | News, opinion and commentary | Leonard Zehr | |||
| Allelix founder quits top jobs. | News, opinion and commentary | Leonard Zehr | |||
| BioChem to target major acquisition, likely in U.S. | News, opinion and commentary | Leonard Zehr | |||
| BioChem wins round to expand way drug used. | News, opinion and commentary | Leonard Zehr | |||
| Biomira breast cancer vaccine shows positive results. | News, opinion and commentary | Leonard Zehr | |||
| Biovail to issue shares for possible 'small niche' U.S. acquisitions. | News, opinion and commentary | Leonard Zehr | |||
| Cambridge plans $700-million strategy. | News, opinion and commentary | Leonard Zehr | |||
| Canadian Medical near U.S. research unit acquisition. | News, opinion and commentary | Leonard Zehr | |||
| Centrefund to purchase 10 shopping centres. | News, opinion and commentary | Leonard Zehr | |||
| ClubLink acquires land for new golf courses. | News, opinion and commentary | Leonard Zehr | |||
| Cobequid puts faith in DNA vaccine. | News, opinion and commentary | Leonard Zehr | |||
| Colliers buys half interest in Cleveland firm. | News, opinion and commentary | Leonard Zehr | |||
| Condos at crossroads? | News, opinion and commentary | Leonard Zehr | |||
| Counsel to sell unit after ditching IPO. | News, opinion and commentary | Leonard Zehr | |||
| Court stays prohibition of generic AZT sales. | News, opinion and commentary | Leonard Zehr | |||
| Draxis predicts win in proxy battle. | News, opinion and commentary | Leonard Zehr | |||
| Draxis revenue jumps 59%. | News, opinion and commentary | Leonard Zehr | |||
| Drug Royalty eyes healthy returns. | News, opinion and commentary | Leonard Zehr | |||
| First Place Tower pursues new debt plan. | News, opinion and commentary | Leonard Zehr | |||
| Generics win major court case. | News, opinion and commentary | Leonard Zehr | |||
| Gentra head says no to privatization. | News, opinion and commentary | Leonard Zehr | |||
| Gentra sees flexibility to make $800-million of acquisitions. | News, opinion and commentary | Leonard Zehr | |||
| Glaxo seeks flu drug approval. | News, opinion and commentary | Leonard Zehr | |||
| Hemosol closes gap in race for human blood substitute. | News, opinion and commentary | Leonard Zehr | |||
| Hyal stock tanks on lost marketing deal. | News, opinion and commentary | Leonard Zehr | |||
| Med-Chem lenders demand repayment of $40-million. | News, opinion and commentary | Leonard Zehr | |||
| Morty Shulman goes to battle again. | News, opinion and commentary | Leonard Zehr | |||
| MUSE impotence drug beats Viagra to market. | News, opinion and commentary | Leonard Zehr | |||
| New office space coming on stream, survey finds. | News, opinion and commentary | Leonard Zehr | |||
| New treatment can fight E. Coli: Nymox. | News, opinion and commentary | Leonard Zehr | |||
| Nexia Biotech produces genetically altered goat. | News, opinion and commentary | Leonard Zehr | |||
| O&Y boosts bond issue to $100-million. | News, opinion and commentary | Leonard Zehr | |||
| RealFund shifts strategy away from acquisitions. | News, opinion and commentary | Leonard Zehr | |||
| Shulman fuels Draxis fued. | News, opinion and commentary | Leonard Zehr | |||
| Swedish drug giant ends development deal with Allelix. | News, opinion and commentary | Leonard Zehr | |||
| Tridel sees debt restructuring talks coming to an end. | News, opinion and commentary | Leonard Zehr | |||
| Trilogy to develop hotel in Vancouver. | News, opinion and commentary | Leonard Zehr | |||
| Trust expects profit on Calgary office development. | News, opinion and commentary | Leonard Zehr | |||
| Visible Genetics reports gains from HIV treatment. | News, opinion and commentary | Leonard Zehr | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.